Our Products

Erlotinib Tablets IP 150 mg is a targeted therapy used primarily for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It is an epidermal growth factor receptor (EGFR) inhibitor, which works by blocking the activity of the EGFR protein on cancer cells. This inhibition prevents the growth and spread of cancer cells that are dependent on EGFR signaling.

The 150 mg dosage is typically taken once daily, with or without food, as prescribed by a healthcare provider. Common side effects of Erlotinib may include skin rash, diarrhea, nausea, fatigue, and liver enzyme abnormalities. Regular monitoring is essential to manage these side effects and assess the effectiveness of treatment.